Scott A. Langenecker, Ph.D.
Associate Professor of Psychiatry and Psychology
University of Illinois at Chicago
Scott A. Langenecker, Ph.D. is a clinical neuropsychologist and Associate Professor of Psychiatry and Psychology. He is a native of rural Wisconsin, and completed his undergraduate work at the University of Wisconsin at Madison. Dr. Langenecker completed his graduate work at Marquette University with a dissertation on life span studies of inhibitory control, with focus on healthy aging and functional MRI, winning an APA dissertation award. He completed his internship at the Albert Einstein North Shore-Long Island Jewish Medical Center in New York. Dr. Langenecker’s fellowship was at the University of Michigan Medical Center in Clinical Neuropsychology, which he completed in 2003, and he was a faculty member at the University of Michigan until July, 2012. He is now the Director of Cognitive Neuroscience at the University of Illinois at Chicago, and Associate Professor with tenure in psychology and psychiatry. He has been actively involved in the Prechter Longitudinal Study of Bipolar Disorder since its inception in 2005.
Dr. Langenecker's research and clinical work focuses on the translational cognitive neuroscience of mood disorders across the lifespan. Specifically, he is involved in studies to understand the cognitive and affective abnormalities observed in depression and bipolar disorder, the neurological (fMRI, PET) underpinnings of these abnormalities, and the ramifications for treatment selection and prognosis. Toward this end, he uses, modifies and develops neuroimaging studies with cognitive and affective challenge paradigms that can be used as translational neuropsychological measures and be administered in clinical settings. Thus, relationships between performance parameters collected in clinical and research settings, and activation (fMRI) and/or binding (PET) measures can offer increased insight into the nature, etiology, and treatment response of mood disorders. Using these strategies to identify depression and bipolar subtypes (e.g., based upon treatment prediction/response, clinical features, behavioral measures, or neural systems parameters) is a key approach toward reducing the negative impact of mood disorders. His current work is focused on the late adolescent translational period in which risk for mood disorders is at a peak.